12 Month Price Forecast For BLTE
Distance to BLTE Price Forecasts
BLTE Price Momentum
๐ค Considering Belite Bio (BLTE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 11:57 AM UTC
BLTE Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, BLTE has a consensus that is bullish. The median price target is $89.50, with forecasts ranging from $50.00 to $110.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With BLTE currently trading at $58.07, the median price forecast suggests a 54.1% upside. The most optimistic forecast comes from Jason McCarthy at Maxim Group, projecting a 89.4% upside, while at provides the most conservative target, suggesting a -13.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLTE Analyst Consensus
BLTE Price Target Range
Latest BLTE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLTE.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 21, 2025 | Benchmark | Bruce Jackson | Buy | Maintains | $79.00 |
Nov 15, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $110.00 |
Nov 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $100.00 |
Sep 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $60.00 |
Aug 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $60.00 |
Aug 13, 2024 | Benchmark | Bruce Jackson | Buy | Reiterates | $57.00 |
Jun 20, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $0.00 |
Jun 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $59.00 |
May 16, 2024 | Benchmark | Bruce Jackson | Buy | Reiterates | $57.00 |
May 15, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $0.00 |
May 15, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $59.00 |
Mar 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $59.00 |
Mar 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $59.00 |
Dec 27, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $59.00 |
Dec 14, 2023 | Maxim Group | Jason McCarthy | Buy | Initiates | $60.00 |
Nov 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $59.00 |
Nov 7, 2023 | Benchmark | Bruce Jackson | Buy | Reiterates | $57.00 |
Nov 6, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $59.00 |
Aug 10, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $55.00 |
Jul 28, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Initiates | $43.00 |
Stocks Similar to Belite Bio, Inc
The following stocks are similar to Belite Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Belite Bio, Inc (BLTE) Financial Data
Belite Bio, Inc has a market capitalization of $1.82B with a P/E ratio of -48.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -40.0%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Belite Bio, Inc (BLTE) Company Overview
About Belite Bio, Inc
Develops therapeutics for retinal degenerative diseases.
Belite Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for retinal degenerative eye diseases. The company primarily generates revenue through the advancement of its drug candidates, such as LBS-008 and LBS-009, which aim to address significant unmet medical needs in the market.
Founded in 2016 and based in San Diego, California, Belite Bio is a subsidiary of Lin Bioscience International Ltd. Its lead product, LBS-008, is designed for once-daily oral administration and targets specific eye conditions, while LBS-009 is in preclinical development for liver-related diseases and type 2 diabetes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
20
CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Country
United States
IPO Year
2022
Website
www.belitebio.comBelite Bio, Inc (BLTE) Latest News & Analysis
Lin BioScience's LBS-007 has received Fast Track Designation from the FDA for acute myeloid leukemia. The company is conducting a phase 1/2 trial and holds orphan drug designations for both AML and ALL.
Lin BioScience's Fast Track Designation for LBS-007 enhances its potential for accelerated market access, increasing investor confidence and interest in its future growth and profitability.
Belite Bio, Inc. (NASDAQ:BLTE) will hold its Q3 2024 earnings conference call on November 12, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
Belite Bio's Q3 earnings call will provide insights into its financial health and strategic direction, impacting stock performance and investor sentiment.
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
3 months agoBelite Bio, Inc (NASDAQ: BLTE) will host a webcast on November 12, 2024, at 4:30 p.m. ET to discuss Q3 2024 financial results and provide a business update.
Belite Bio's upcoming webcast will reveal key financial results and business developments, impacting investor sentiment and stock performance for the clinical-stage biopharmaceutical company.
Belite Bio has entered into an agreement to exercise warrants for 651,380 shares at $44.14 each, raising approximately $28.75 million for general corporate purposes.
Belite Bio's warrant exercise indicates strong investor confidence, raising $28.75 million for development. This financial boost can accelerate research, impacting future growth and stock performance.
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
5 months agoBelite Bio (NASDAQ: BLTE) appointed Dr. Hendrik P. N. Scholl as Chief Medical Officer, effective immediately. He is an expert in Stargardt disease and AMD, key areas for Belite's lead drug, Tinlarebant.
The appointment of a renowned expert as CMO enhances Belite Bio's credibility and could accelerate drug development, potentially leading to increased investor confidence and stock value.
Belite Bio, Inc (NASDAQ:BLTE) will hold its Q2 2024 earnings conference call on August 12, 2024, at 4:30 PM ET, featuring key executives and analysts from various firms.
The Q2 2024 earnings call for Belite Bio will provide insights into the company's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Frequently Asked Questions About BLTE Stock
What is Belite Bio, Inc's (BLTE) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Belite Bio, Inc (BLTE) has a median price target of $89.50. The highest price target is $110.00 and the lowest is $50.00.
Is BLTE stock a good investment in 2025?
According to current analyst ratings, BLTE has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $58.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BLTE stock?
Wall Street analysts predict BLTE stock could reach $89.50 in the next 12 months. This represents a 54.1% increase from the current price of $58.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Belite Bio, Inc's business model?
Belite Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for retinal degenerative eye diseases. The company primarily generates revenue through the advancement of its drug candidates, such as LBS-008 and LBS-009, which aim to address significant unmet medical needs in the market.
What is the highest forecasted price for BLTE Belite Bio, Inc?
The highest price target for BLTE is $110.00 from Jason McCarthy at Maxim Group, which represents a 89.4% increase from the current price of $58.07.
What is the lowest forecasted price for BLTE Belite Bio, Inc?
The lowest price target for BLTE is $50.00 from at , which represents a -13.9% decrease from the current price of $58.07.
What is the overall BLTE consensus from analysts for Belite Bio, Inc?
The overall analyst consensus for BLTE is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $89.50.
How accurate are BLTE stock price projections?
Stock price projections, including those for Belite Bio, Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.